AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6800465 — intervention group
Group type: EXPERIMENTAL
Intervention: 1850 APTT units of low‐molecular‐weight heparin as a single injection
Number of subjects: 150
Study 6800465 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐molecular‐weight heparin
Number of subjects: 150
Study 6800465 — intervention group
Group type: COMPARATOR
Intervention: Equal amounts of low‐molecular‐weight heparin and unfractionated heparin
Number of subjects: 150
Study 31812557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch foods presented at breakfast time (incongruous meal context)
Number of subjects: 40
Study 31812557 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast foods at lunch (incongruous meal context)
Number of subjects: 40
Study 31812557 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast foods at breakfast time (congruous meal context)
Number of subjects: 40
Study 31812557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch foods at lunch time (congruous meal context)
Number of subjects: 40
Study 31345973 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy treatment
Number of subjects: 273
Study 28591280 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injections into the orbicularis muscle
Number of subjects: 40
Study 28591280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 26602423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented, protein-fortified dairy product (15 g protein/150 g)
Number of subjects: 62
Study 26602423 — intervention group
Group type: COMPARATOR
Intervention: Control (3 g protein/150 g)
Number of subjects: 62
Study 26602423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented, protein-fortified dairy product
Number of subjects: 62
Study 26602423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented, protein-fortified dairy product (higher protein group)
Number of subjects: 62
Study 24337761 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day for 15 days
Number of subjects: 83
Study 24337761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 21855271 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal surface treatment with hydroxyapatite coating
Number of subjects: 55
Study 21855271 — intervention group
Group type: COMPARATOR
Intervention: Proximal surface treatment without hydroxyapatite coating
Number of subjects: 55
Study 19170905 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract (RVOT) septal pacing
Number of subjects: 100
Study 17445337 — intervention group
Group type: EXPERIMENTAL
Intervention: NCEP step II diet
Number of subjects: 44
Study 17445337 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 44
Study 15453897 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor training with home biofeedback
Number of subjects: 35
Study 15453897 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor training alone
Number of subjects: 35
Study 11235062 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural progesterone creams
Number of subjects: 0
Study 9683116 — intervention group
Group type: EXPERIMENTAL
Intervention: Geragogy-based medication instruction
Number of subjects: 60
Study 9683116 — intervention group
Group type: COMPARATOR
Intervention: Usual preprinted discharge instructions with handwritten medication information
Number of subjects: 60
Study 8210018 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia (group I n = 12)
Number of subjects: 24
Study 8210018 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia (group 2 n = 12)
Number of subjects: 24
Study 2810090 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mm intraocular lens without positioning holes
Number of subjects: 550
Study 2810090 — intervention group
Group type: COMPARATOR
Intervention: 7 mm intraocular lens with positioning holes
Number of subjects: 550
Study 2810090 — intervention group
Group type: COMPARATOR
Intervention: Partial depth holes
Number of subjects: 550
Study 52209 — intervention group
Group type: EXPERIMENTAL
Intervention: Health educational measures that motivate patients towards personal activity
Number of subjects: 0
Study 52209 — intervention group
Group type: COMPARATOR
Intervention: Passive forms of health education (information, instruction, demonstration)
Number of subjects: 0
Study 31657838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraud FAPs
Number of subjects: 8204
Study 31657838 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient harm FAPs
Number of subjects: 8204
Study 31657838 — intervention group
Group type: EXPERIMENTAL
Intervention: Revoked license FAPs
Number of subjects: 8204
Study 29391150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 20
Study 29391150 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 20
Study 29391150 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow
Number of subjects: 20
Study 29391150 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow
Number of subjects: 20
Study 27760062 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 413
Study 27760062 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) and Cognitive Behavioral Therapy (CBT)
Number of subjects: 413
Study 27760062 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) and Seal Oil
Number of subjects: 413
Study 27760062 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) and Soy Oil
Number of subjects: 413
Study 27760062 — intervention group
Group type: COMPARATOR
Intervention: Control (BI)
Number of subjects: 413
Study 24481483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 medications
Number of subjects: 603
Study 24481483 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 medication
Number of subjects: 603
Study 24481483 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 medications
Number of subjects: 603
Study 24481483 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 medications
Number of subjects: 603
Study 22489518 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation treatment assisted with orthopedic footwear
Number of subjects: 44
Study 22489518 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulation treatment only (Control)
Number of subjects: 44
Study 20857329 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk neighborhood environments
Number of subjects: 384
Study 20857329 — intervention group
Group type: COMPARATOR
Intervention: Low risk neighborhood environments
Number of subjects: 384
Study 17594680 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15454356 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month combined dietary and breast health intervention
Number of subjects: 256
Study 15454356 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving mailed health education material
Number of subjects: 256
Study 11673330 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdysgenesis features in patients with seizure-free outcome (Class I)
Number of subjects: 0
Study 11673330 — intervention group
Group type: COMPARATOR
Intervention: White matter ND
Number of subjects: 0
Study 9675742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based mass screening for AAA with revised appointment and reinvitation of non-responders.
Number of subjects: 4404
Study 7926297 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to 37k antigen
Number of subjects: 0
Study 7926297 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibodies to GAD
Number of subjects: 0
Study 7926297 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD antibody levels
Number of subjects: 0
Study 7926297 — intervention group
Group type: EXPERIMENTAL
Intervention: IAAs
Number of subjects: 0
Study 2574190 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nizatidine every 8 hours
Number of subjects: 10
Study 2574190 — intervention group
Group type: COMPARATOR
Intervention: 150 mg nizatidine every 12 hours
Number of subjects: 10
Study 15523485 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction diet for 10 weeks
Number of subjects: 20
Study 31242931 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg/day), administered as a transdermal patch by paramedics in the prehospital setting within 3 h of stroke onset and continued for 24 h
Number of subjects: 1400
Study 31242931 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1400
Study 28396516 — intervention group
Group type: EXPERIMENTAL
Intervention: D. genkwa root extractive
Number of subjects: 60
Study 28396516 — intervention group
Group type: COMPARATOR
Intervention: Control group (without D. genkwa extractive)
Number of subjects: 60
Study 26522892 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 10mg (0.4mL) of bevacizumab
Number of subjects: 7
Study 26522892 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin (6mg/m²)
Number of subjects: 7
Study 26522892 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment: subconjunctival injection of bevacizumab followed by photodynamic therapy 7 days later
Number of subjects: 7
Study 23537173 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoaging information
Number of subjects: 0
Study 23537173 — intervention group
Group type: EXPERIMENTAL
Intervention: UV photo
Number of subjects: 0
Study 23537173 — intervention group
Group type: EXPERIMENTAL
Intervention: Both photoaging information and UV photo
Number of subjects: 0
Study 23537173 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention
Number of subjects: 0
Study 23537173 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoaging information and UV photo
Number of subjects: 0
Study 21193187 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 114
Study 21193187 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 114
Study 20128319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec Plus varnish
Number of subjects: 58
Study 20128319 — intervention group
Group type: COMPARATOR
Intervention: Cervitec varnish
Number of subjects: 58
Study 20128319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both varnishes
Number of subjects: 58
Study 16179819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton Bract Extract (CBE)
Number of subjects: 21
Study 16179819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton Dust Extract (CDE)
Number of subjects: 21
Study 16179819 — intervention group
Group type: COMPARATOR
Intervention: Methacholine (MCh) response
Number of subjects: 21
Study 15139567 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI 20/50 (IB 20 microg/FEN 50 microg)
Number of subjects: 892
Study 15139567 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat SMI 10/25 (IB 10 microg/FEN 25 microg)
Number of subjects: 892
Study 15139567 — intervention group
Group type: COMPARATOR
Intervention: CFC-MDI 40/100 (IB 20 microg/FEN 50 microg)
Number of subjects: 892
Study 15139567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Respimat SMI)
Number of subjects: 892
Study 15139567 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CFC-MDI)
Number of subjects: 892
Study 11284817 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 10 microg.kg‐1
Number of subjects: 20
Study 11284817 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1.5 mg.kg‐1
Number of subjects: 20
Study 9253097 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training program
Number of subjects: 153
Study 9253097 — intervention group
Group type: EXPERIMENTAL
Intervention: TerapiMaster training program
Number of subjects: 153
Study 9253097 — intervention group
Group type: COMPARATOR
Intervention: Both training programs
Number of subjects: 153
Study 8516520 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.13 mg/kg)
Number of subjects: 26
Study 8516520 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg)
Number of subjects: 26
Study 2434789 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (800, 1,600, or 3,200 micrograms/kg/h)
Number of subjects: 20
Study 2434789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (200, 400, or 800 micrograms/kg/h)
Number of subjects: 20
Study 29352425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin (80 mg daily)
Number of subjects: 54
Study 29352425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29352425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 54
Study 27496096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy plus medical treatment with slow release bupropion)
Number of subjects: 210
Study 27496096 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy)
Number of subjects: 210
Study 27496096 — intervention group
Group type: COMPARATOR
Intervention: Control (just TB medical treatment)
Number of subjects: 210
Study 24268677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis Bl‐04 2.0 × 10(9) CFU per day
Number of subjects: 465
Study 24268677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi‐07 5 × 10(9) CFU each per day
Number of subjects: 465
Study 24268677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 24268677 — intervention group
Group type: EXPERIMENTAL
Intervention: NCFM & Bi‐07 group
Number of subjects: 465
Study 21885174 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol, 1 or 2 μg/d for 16 weeks
Number of subjects: 80
Study 21885174 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol, 50,000 units titrated to achieve serum levels ≥30 ng/mL for 16 weeks
Number of subjects: 80
Study 20432110 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for prostate cancer screening
Number of subjects: 200
Study 20432110 — intervention group
Group type: COMPARATOR
Intervention: No exposure to decision aid (Control)
Number of subjects: 200
Study 25159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention techniques delivered in ProActive
Number of subjects: 365
Study 25159905 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant talk during intervention
Number of subjects: 365
Study 14711888 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL glucose 30%
Number of subjects: 58
Study 14711888 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mL glucose 30%
Number of subjects: 58
Study 14711888 — intervention group
Group type: COMPARATOR
Intervention: 2 mL water (control)
Number of subjects: 58
Study 11376913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion into the masseter muscle
Number of subjects: 22
Study 11376913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion into the anterior tibialis muscle
Number of subjects: 22
Study 11376913 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched subjects)
Number of subjects: 22
Study 11376913 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived area of experimental masseter pain
Number of subjects: 22
Study 11376913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) in the masseter
Number of subjects: 22
Study 11376913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) in the anterior tibialis
Number of subjects: 22
Study 11376913 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain thresholds (HPTs) in the masseter
Number of subjects: 22
Study 11376913 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat pain thresholds (HPTs) in the anterior tibialis
Number of subjects: 22
Study 9246149 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg BID
Number of subjects: 402
Study 9246149 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 8 mg TID
Number of subjects: 402
Study 8432921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injections of allergen-antibody complexes
Number of subjects: 24
Study 8432921 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 3109461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mesna (800 mg)
Number of subjects: 6
Study 3109461 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mesna (800 mg)
Number of subjects: 6
Study 30721390 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizer (JN)
Number of subjects: 14
Study 30721390 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer integrated in high flow nasal cannulas (NHF)
Number of subjects: 14
Study 30721390 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPE monitoring
Number of subjects: 14
Study 29800034 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human pentraxin 2 (10 mg/kg intravenous every 4 weeks, n=77)
Number of subjects: 117
Study 29800034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=39)
Number of subjects: 117
Study 29800034 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human pentraxin 2
Number of subjects: 117
Study 29800034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 26691411 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aquatic exercise for 80 minutes
Number of subjects: 35
Study 26691411 — intervention group
Group type: COMPARATOR
Intervention: Calm sitting position for 80 minutes
Number of subjects: 35
Study 24166586 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Adefovir plus 100 mg Lamivudine (combination therapy)
Number of subjects: 122
Study 24166586 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Adefovir (monotherapy)
Number of subjects: 122
Study 22108629 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 22108629 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 20661939 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐g Semmes‐Weinstein monofilament and 128‐Hz tuning fork examinations
Number of subjects: 1193
Study 17131307 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-detector multi-slice computed tomography screening
Number of subjects: 15428
Study 17131307 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 15428
Study 15227760 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based instruction (5 hours) and classroom curriculum (10 hours)
Number of subjects: 0
Study 15227760 — intervention group
Group type: COMPARATOR
Intervention: Standard school curriculum nutrition education
Number of subjects: 0
Study 11115342 — intervention group
Group type: EXPERIMENTAL
Intervention: Active foot compression device (functioning)
Number of subjects: 115
Study 11115342 — intervention group
Group type: COMPARATOR
Intervention: Placebo foot compression device (nonfunctioning)
Number of subjects: 115
Study 11115342 — intervention group
Group type: EXPERIMENTAL
Intervention: Active foot compression device (functioning) - compliant subgroup
Number of subjects: 115
Study 11115342 — intervention group
Group type: COMPARATOR
Intervention: Placebo foot compression device (nonfunctioning) - compliant vs noncompliant
Number of subjects: 115
Study 11115342 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of groups
Number of subjects: 115
Study 9570681 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0
Study 9570681 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 0
Study 9570681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensified chemotherapy
Number of subjects: 0
Study 9570681 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose therapy
Number of subjects: 0
Study 8315261 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation (3000 units initially, followed by 1000 units every 6 hours)
Number of subjects: 25
Study 8315261 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 3717101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline sulfate, 5 mg twice daily
Number of subjects: 20
Study 3717101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline sulfate, 7.5 mg twice daily
Number of subjects: 20
Study 3717101 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (doses adjusted to achieve serum concentrations of 10 to 20 mg/L)
Number of subjects: 20
Study 3717101 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 20
Study 30081329 — intervention group
Group type: EXPERIMENTAL
Intervention: OHRQoL measured by OHIP‐14T
Number of subjects: 517
Study 30081329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status measured by MNA
Number of subjects: 517
Study 30081329 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL measured by WHOQOL‐BREF
Number of subjects: 517
Study 30081329 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall model
Number of subjects: 517
Study 28019085 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-rich food
Number of subjects: 120
Study 28019085 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-enriched yeast and astaxanthin oil
Number of subjects: 120
Study 28019085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26694426 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing green scenes
Number of subjects: 46
Study 26694426 — intervention group
Group type: COMPARATOR
Intervention: Viewing built scenes
Number of subjects: 46
Study 23273853 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented mental practice (MP) approach, performed for 6 weeks, at least 3 times per day, using video-instructed MP.
Number of subjects: 0
Study 23273853 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental therapy-based exercise therapy (Control group).
Number of subjects: 0